These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24874841)

  • 1. High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.
    Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2014 Jun; 21(6):256-60. PubMed ID: 24874841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.
    Ayala Breton C; Wikan N; Abbuhl A; Smith DR; Russell SJ; Peng KW
    Mol Ther Oncolytics; 2015; 2():15012. PubMed ID: 27119107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
    Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
    Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
    Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic measles virus retargeting by ligand display.
    Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
    Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
    Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
    Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
    Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E
    Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
    Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
    Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
    Jing Y; Bejarano MT; Zaias J; Merchan JR
    Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
    Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
    Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
    Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
    Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
    Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.